Shots: Seed Therapeutics to receive $10M upfront, $10M equity investment, ~$780M as pre/clinical development, regulatory & commercial milestones along with royalties on net sales of products that emerges from the collaboration Seed utilizes molecular glue protein degradation technology to develop potential new therapies The agreement allows Seed to advance its platform to deliver new molecules […]Read More
